To include your compound in the COVID-19 Resource Center, submit it here.

Syros' SY-1425 plus Vidaza leads to 63% ORR in biomarker-positive AML cohort

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) reported Phase II data from a cohort of eight evaluable newly diagnosed, biomarker-positive acute myelogenous leukemia (AML) patients showing that tamibarotene (SY-1425) plus Vidaza

Read the full 286 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE